Shanghai Pharmaceuticals Holding Co. and Johnson & Johnson have reached a strategic cooperation agreement in the long-acting injection field of CNS (central nervous system).

On April 15th, Sundy Health announced that it has officially reached a nationwide strategic cooperation with Johnson & Johnson in the field of long-acting injections for CNS. Sundy Health's subsidiary, Lingyao Health, signed an exclusive marketing agreement with Johnson & Johnson, taking full responsibility for the marketing of the long-acting injections for schizophrenia, Sunyee, Sunwayee, and Sunjuee in mainland China.